Healthcare Equipment and Supplies
Company Overview of Baxter Healthcare Corporation
Baxter Healthcare Corporation develops, manufactures, and markets healthcare equipment and instruments. It focuses on critical therapies for life-threatening conditions, specifically with products and services in blood therapies, cardiovascular medicine, medication delivery, and renal therapy. The company offers its products in the United States and internationally. The company was formerly known as Travenol Laboratories, Inc. and changed its name to Baxter Healthcare Corporation in July 1987. The company was incorporated in 1966 and is based in Deerfield, Illinois. Baxter Healthcare Corporation operates as a subsidiary of Baxter International Inc.
One Baxter Parkway
Deerfield, IL 60015-4633
Founded in 1966
Key Executives for Baxter Healthcare Corporation
Compensation as of Fiscal Year 2014.
Baxter Healthcare Corporation Key Developments
Rockwell Medical, Inc. Signs an Exclusive Agreement with Baxter Healthcare Corporation
Oct 3 14
Rockwell Medical, Inc. signed an exclusive agreement with Baxter Healthcare Corporation, to commercialize Rockwell's hemodialysis concentrate product line in the U.S. and in select overseas markets. Under the terms of the agreement, Baxter will become the exclusive distributor of Rockwell's hemodialysis concentrate and ancillary products in the U.S. and selected foreign countries for an initial term of 10 years. Baxter can extend the agreement for two additional 5-year terms upon meeting certain sales targets, coupled with a $7.5 million payment related to the first extension. Baxter will purchase products from Rockwell at a pre-determined gross margin-based price per unit and is required to meet minimum annual purchase levels in order to retain their exclusive rights. Baxter will leverage Rockwell's unique distribution operations in order to provide specialized customer and delivery service for concentrates, covering Rockwell's costs for these services. Rockwell will retain sales, marketing and distribution rights for its hemodialysis concentrate products in certain foreign countries in which it has an established commercial presence.
Baxter Healthcare Corporation Announces Signing of New Lease to Establish New Global Innovation and Research and Development Center
Sep 29 14
BioMed Realty Trust Inc. announced the signing of a new lease for approximately 200,000 square feet for 12 years with Baxter Healthcare Corporation at 650 East Kendall Street in Cambridge, Massachusetts. Baxter will be establishing a new global innovation and research and development (R&D) center at the site for its biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta Incorporated in mid-2015.
APP Pharmaceuticals L.L.C. and Baxter Healthcare Corp. Provide Update on Lawsuit
Nov 8 13
The U.S. District Court for the Middle District of Pennsylvania denied in relevant part a motion by two pharmaceutical companies for summary judgment in an action brought by a former patient alleging strict liability arising from the companies failure to warn the patient's physician of side effects associated with Heparin. Edward Dreisbach sued APP Pharmaceuticals L.L.C., Baxter Healthcare Corp. and other parties, alleging strict liability claims arising from the defendants failure to warn of specific risks of serious side effects associated with Heparin, including Heparin-induced thrombocytopenia and Heparin-induced thrombocytopenia with thrombus. APP and Baxter moved for summary judgment. In a prior ruling, the district court denied the defendants motion to exclude the plaintiff's expert testimony as to the adequacy of the warnings provided by the defendants. The court found the plaintiff's expert raised a fact issue as to the adequacy of the warnings and, accordingly, the defendants related motion for summary judgment was denied. The court noted the defendants second ground for summary judgment was that Dreisbach failed to establish proximate causation between the allegedly inadequate warning and his injury. The defendants argued that because Dreisbach's physicians did not read the Heparin label, were aware of the risks of HITT and stood by their decisions to prescribe Heparin, Dreisbach could not prove that the alleged inadequate warning was a substantial factor in bringing about the harm he suffered. The court recognized that Dreisbach's physicians had a duty to use their independent judgment in deciding what form of anticoagulant to use on a specific patient. The court noted that neither party asked one of Dreisbach's treating physicians if he would have given Dreisbach Heparin had he received Dreisbach's proposed warnings. Instead, the physician was asked whether he would be able to follow a dear healthcare provider letter, providing that the duration of heparin should be limited, whenever possible, to less than five days. The court found the record raised a material fact as to causation because it was unclear whether the physician was testifying to the fact that he would have been able to follow an instruction to use Heparin for less than five days specifically in the plaintiff's case. Accordingly, and after finding no merit to the defendants remaining arguments, the district court denied in part the defendants motion for summary judgment.
Similar Private Companies By Industry
Recent Private Companies Transactions